New perspectives on the biology of acute GVHD
- PMID: 19946340
- PMCID: PMC7793552
- DOI: 10.1038/bmt.2009.328
New perspectives on the biology of acute GVHD
Abstract
The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have been developed for transplantation in patients who previously would not have been considered HCT candidates. However, its efficacy continued to be limited by the development of frequent and severe acute GVHD. The complex and intricate pathophysiology of acute GVHD is a consequence of interactions between the donor and host innate and adaptive immune responses. Multiple inflammatory molecules and cell types are implicated in the development of GVHD that can be categorized as: (1) triggers that initiate GVHD by therapy-induced tissue damage and the antigen disparities between host and graft tissue; (2) sensors that detect the triggers, that is, process and present alloantigens; (3) mediators such as T-cell subsets (naive, memory, regulatory, Th17 and natural killer T cells) and (4) the effectors and amplifiers that cause damage of the target organs. These multiple inflammatory molecules and cell types that are implicated in the development of GVHD have been described with models that use stepwise cascades. Herein, we provide a novel perspective on the immunobiology of acute GVHD and briefly discuss some of the outstanding questions and limitations of the model systems.
Conflict of interest statement
Conflict of interest
The authors declare no conflict of interest.
Figures




Similar articles
-
Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Transplantation. 2008 Feb 15;85(3):303-8. doi: 10.1097/TP.0b013e318162d357. Transplantation. 2008. PMID: 18301323 Review.
-
Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.Biol Blood Marrow Transplant. 2018 Aug;24(8):1563-1574. doi: 10.1016/j.bbmt.2018.04.016. Epub 2018 Apr 17. Biol Blood Marrow Transplant. 2018. PMID: 29678638
-
Graft-versus-host disease.Panminerva Med. 2010 Jun;52(2):111-24. Panminerva Med. 2010. PMID: 20517195 Review.
-
GVHD pathophysiology: is acute different from chronic?Best Pract Res Clin Haematol. 2008 Jun;21(2):101-17. doi: 10.1016/j.beha.2008.02.005. Best Pract Res Clin Haematol. 2008. PMID: 18503979 Review.
-
Advances in understanding the pathogenesis of graft-versus-host disease.Br J Haematol. 2016 Apr;173(2):190-205. doi: 10.1111/bjh.13959. Epub 2016 Mar 27. Br J Haematol. 2016. PMID: 27019012 Review.
Cited by
-
HTLV-1 infection of donor-derived T cells might promote acute graft-versus-host disease following liver transplantation.Nat Commun. 2022 Nov 30;13(1):7368. doi: 10.1038/s41467-022-35111-w. Nat Commun. 2022. PMID: 36450748 Free PMC article.
-
Prevention of graft-vs.-host disease.Expert Opin Pharmacother. 2012 Aug;13(12):1737-50. doi: 10.1517/14656566.2012.703652. Epub 2012 Jul 7. Expert Opin Pharmacother. 2012. PMID: 22770714 Free PMC article. Review.
-
IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects.Leukemia. 2015 Apr;29(4):939-46. doi: 10.1038/leu.2014.310. Epub 2014 Nov 3. Leukemia. 2015. PMID: 25363669 Free PMC article.
-
TLR4 inactivation protects from graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Cell Mol Immunol. 2013 Mar;10(2):165-75. doi: 10.1038/cmi.2012.58. Epub 2012 Dec 24. Cell Mol Immunol. 2013. PMID: 23262974 Free PMC article.
-
TCF-1 Is Required for CD4 T Cell Persistence Functions during AlloImmunity.Int J Mol Sci. 2023 Feb 21;24(5):4326. doi: 10.3390/ijms24054326. Int J Mol Sci. 2023. PMID: 36901757 Free PMC article.
References
-
- Billingham RE. The biology of graft-versus-host reactions.Harvey Lect 1966-67; 62: 21–78. - PubMed
-
- Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415. - PubMed
-
- Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005; 11: 1244–1249. - PubMed
-
- Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10: 987–992. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources